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Laura J. Dumas,1 Majesta S. O’Bleness,1 Jonathan M. Davis,1,2 C. Michael Dickens,1 Nathan Anderson,1
J.G. Keeney,1 Jay Jackson,1 Megan Sikela,1 Armin Raznahan,3 Jay Giedd,3 Judith Rapoport,3
Sandesh S.C. Nagamani,4 Ayelet Erez,4 Nicola Brunetti-Pierri,5,6 Rachel Sugalski,7 James R. Lupski,4
Tasha Fingerlin,2 Sau Wai Cheung,4 and James M. Sikela1,*
DUF1220 domains show the largest human-lineage-specific increase in copy number of any protein-coding region in the human
genome and map primarily to 1q21, where deletions and reciprocal duplications have been associated with microcephaly and macro-
cephaly, respectively. Given these findings and the high correlation between DUF1220 copy number and brain size across primate line-
ages (R2 ¼ 0.98; p ¼ 1.8 3 106), DUF1220 sequences represent plausible candidates for underlying 1q21-associated brain-size pathol-
ogies. To investigate this possibility, we used specialized bioinformatics tools developed for scoring highly duplicated DUF1220
sequences to implement targeted 1q21 array comparative genomic hybridization on individuals (n ¼ 42) with 1q21-associated micro-
cephaly and macrocephaly. We show that of all the 1q21 genes examined (n ¼ 53), DUF1220 copy number shows the strongest asso-
ciation with brain size among individuals with 1q21-associated microcephaly, particularly with respect to the three evolutionarily
conserved DUF1220 clades CON1(p ¼ 0.0079), CON2 (p ¼ 0.0134), and CON3 (p ¼ 0.0116). Interestingly, all 1q21 DUF1220-encoding
genes belonging to the NBPF family show significant correlations with frontal-occipital-circumference Z scores in the deletion group. In
a similar survey of a nondisease population, we show that DUF1220 copy number exhibits the strongest correlation with brain gray-
matter volume (CON1, p ¼ 0.0246; and CON2, p ¼ 0.0334). Notably, only DUF1220 sequences are consistently significant in both
disease and nondisease populations. Taken together, these data strongly implicate the loss of DUF1220 copy number in the etiology
of 1q21-associated microcephaly and support the view that DUF1220 domains function as general effectors of evolutionary, patholog-
ical, and normal variation in brain size.Introduction
DUF1220 protein domains are approximately 65 amino
acids in length and have undergone unusually rapid and
extensive copy-number expansion during recent primate
evolution and most strikingly in the human lineage.1
The first DUF1220-encoding gene identified as a dramatic
human-lineage-specific (HLS) increase in copy number
was MGC8902 (cDNA IMAGE 843276) and was the result
of a genome-wide survey of gene copy-number change
among human and great-ape lineages.2 The same gene
family (now termed the neuroblastoma breakpoint family
[NBPF]) was independently identified when one of its
members was found to be disrupted by a rearrangement
in an individual with neuroblastoma (MIM 613017).3
Analysis of DUF1220 sequences indicated that the domain
shows an exceptional HLS copy-number expansion that
decreases generally with evolutionary distance from hu-
mans, shows signs of positive selection at the coding-
sequence level, and in the brain, exhibits neuron-specific
expression.1,4 Analysis of DUF1220 copy number in the
genomes of 36 mammalian species confirmed that the
highest copy number is found in humans (272).5 In other
species, copy number ranges from a high of 125 in chimps1Department of Biochemistry and Molecular Genetics and Human Medical Ge
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marmosets, 4 in dolphins, only 1 in mice, and none
outside of mammals.
DUF1220 sequences exist within two very distinct
genomic environments: as a single (ancestral) domain in
PDE4DIP (myomegalin) and as multiple tandem copies in
the NBPF multigene family. Only the second form has
undergoneanevolutionarily rapidand recent copy-number
expansion. Excluding the ancestral DUF1220 domain, the
remaining DUF1220-domain-encoding DNA sequences
can be divided into six subgroups, or clades, designated
HLS1, HLS2, HLS3, CON1, CON2, and CON3.5 The copy
number of DUF1220 sequences that belong to HLS clades
has increased markedly in the human lineage, whereas
the copy number of DUF1220 sequences belonging to
CONclades ismore similar across primates andnonprimate
mammals.5
Numerous copy-number variations (CNVs) in the
1q21.1-1q21.2 region, where most DUF1220 sequences
map, have been implicated in an increasingly large
number of recurrent human diseases (Table S1, available
online). Interestingly, two independent reports have found
that deletions within this region are associated withmicro-
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macrocephaly (MIM 612475),6,7 indicating that the dosage
of one or more sequences in this interval affects human
brain size. We have noted that although these implicated
1q21 CNVs contain a number of non-NBPF genes, they
also encompass or immediately flank DUF1220
sequences,8 which, because of their highly duplicated
character, were not directly examined in these previous
studies. To address this issue, we developed custom, high-
resolution, targeted 1q21 oligonucleotide arrays that
included highly-duplicated sequences (e.g., of DUF1220)
in order to identify causal genomic sequences underlying
1q21-associated brain-size variations in disease and nondi-
sease populations.Material and Methods
DUF1220 Copy Number versus Brain Graphs
DUF1220 association with copy number, brain weight, and
cortical neuron counts were graphed with Excel. The relationships
were evaluated by ordinary least-squares (simple linear) regression
with R version 2.10.1. Brain weights were taken from Falk,9 Kou-
prina et al.,10 Roth and Dicke,11 and Ponce de Leon,12 and neuron
counts were from Roth and Dicke.11Genomic DNA Samples
The Medical Genetics Laboratories (Cytogenetic and Microarray
Laboratories) at Baylor College of Medicine provided DNA isolated
from the blood of individuals affected with microcephaly or mac-
rocephaly. The samples provided included 28 individuals with
previously reported6 1q21 deletions or duplications and micro-
cephaly or macrocephaly and were ascertained from a larger
survey of more than 16,000 individuals. From the same laboratory,
an additional 14 samples, which were not previously assayed on
low-resolution arrays, were included in this study. Collaborating
labs (of A.R., J.G., and J.R.) from the National Institute for Mental
Health provided DNA samples (extracted from immortalized cell
lines according to standard methods [QIAGEN, MD, USA]) from
normal individuals at the extremes of high and low brain size.
The presence of extreme brain size was determined on the basis
of residual volumes of total brain, total gray matter, and total
white matter after age and sex were accounted for in a large (n >
300) brain structural magnetic resonance image (sMRI) database.
Brain sMRI scans were all T-1 weighted images with contiguous
1.5 mm axial slices and 2.0 mm coronal slices and were obtained
on the same 1.5-T General Electric (Milwaukee, WI) Signa scanner
with a three-dimensional spoiled gradient-recalled echo sequence.
The aforementioned volumetric indices were derived for each
scan with the use of a previously described,13 well-validated, and
fully automated image-processing pipeline. All procedures fol-
lowed were in accordance with the ethical standards of the respon-
sible committee on human experimentation (institutional and
national), and proper informed consent was obtained.Design of Custom High-Density 1q21.1-1q21.2 DNA
Microarrays
In order to detect CNVs in DUF1220-domain-encoding sequences
in the 1q21.1-1q21.2 region of the genome among individuals, we
designed high-density custom human microarrays by using Agi-
lent Technologies 8x60K platform. The array was enriched forThe Americanboth unique and nonunique 60mer probe sequences that mapped
to Chr 1: 141–150Mb. The arrays were designed prior to the release
of the 2009 human genome assembly (hg19) and were therefore
generated with the 2006 human genome assembly (hg18). The
nonunique probes from chromosome 1, including DUF1220-
domain-encoding sequences, were specific to 1q21 gene regions.
On average, the probe coverage on chromosome 1 included 8–9
probes per 1 kb. A total of 43,010 probes were located on chromo-
some 1. The remaining 15,500 probes were randomly chosen and
mapped to unique regions from the rest of the genome (hg18).aCGH Assays
Oxford Gene Technology (OGT) performed the array comparative
genomic hybridization (aCGH) as an Agilent certified service
provider. OGT utilized the following protocols for preparation of
the test and reference samples: Agilent Oligonucleotide Array-
Based CGH for Genomic DNA Analysis, Enzymatic Labeling for
Blood, Cells, or Tissues (with a High Throughput option) version
6.3, October 2010 (G4410-90010); and Agilent Oligonucleotide
Array-Based CGH for Genomic DNA Analysis, Enzymatic Labeling
for Blood, Cells, or Tissues (with a High Throughput option)
version 6.2.1, February 2010 (G4410-90010).
The Agilent Genomic DNA Enzymatic Labeling Kit (Agilent p/n
5190-0449) was used for labeling the samples. Protocols were
adhered to with the restriction-digest option and with the 96-
well clean-up option (AutoScreen-96A Well plates GE Healthcare
p/n 25-9005-98). A Little Dipper (Scigene) was used for automated
slide washing under ozone-controlled conditions. Slides were
acetonitrile dipped for 1 min after slide washing (wash 1 and
wash 2) for the reduction of slide background. Because high-back-
ground slide quality-control (QC) metrics were observed with the
chromosome 1 array design, all slides were washed twice before
scanning. Slides were scanned on an Agilent C scanner under
ozone-controlled conditions. Data were extracted from the TIFF
images with Agilent Feature Extraction software (version 10.7.1).
All sample- and slide-processing steps and QC metrics were re-
corded in OGT’s Laboratory Information Management System.
So that all test samples could be compared to one another, the
same single unaffected male DNA sample was used as a reference
sample for all experiments.Analysis of aCGH Data
The custom 1q21microarray was composed of probes correspond-
ing to both unique and nonunique sequences, and approximately
75% of the probes were located on chromosome 1. The nonunique
probes have sequences that are found at multiple loci in the
human genome, and the majority of them are located within
the highly duplicated DUF1220-domain-encoding regions. The
original design of the microarray probe sequences was based on
the hg18 2006 assembly, which was converted to the hg19 build
as follows. All 57,897 genomic probe sequences on the microarray
were aligned to the hg19 2009 assembly with BLAT. If a BLAT
search resulted in a match of at least 59 of 60 nucleotides of
each probe sequence, that probe sequence was retained and map-
ped according to the 2009 assembly and was used in the aCGH
analysis. This remapping of the original 57,897 probes resulted
in 267,841 genomic probe loci in the data set so that the
nonunique probes were remapped to all loci determined by the
BLAT alignment results. The log2 ratios for the nonunique array
probes were assigned to each newly mapped nonunique probe
locus. In summary, a specific probe that was originally assignedJournal of Human Genetics 91, 444–454, September 7, 2012 445
to one genomic locus was remapped to multiple loci. The log2
ratios for probes that mapped to the same location were averaged.
Specific steps of the aCGH analysis are described in Figure S1A
and are as follows. For each array experiment, the TIFF image of
the array was imported into Agilent Feature Extraction Software
version 10.7.3.1 for image analysis, which included dye-bias
normalization and data extraction (Figure S1A, step 1).
Dye-Bias Normalization
The dye-bias normalization excluded all probes on chromosomes
1, X, and Y. The chromosome 1 probes were omitted for normali-
zation methods because the majority of these probes were not
unique on the basis of the array design. Additionally, probes on
chromosomes X and Y were omitted for alleviating any bias
created from test and reference samples that were not matched
for sex.
Across-Array Normalization
So that data could be compared between experiments, an across-
array normalization was carried out as follows. After the dye-
normalized log10 ratio for each probe was converted to a linear
ratio, all probes corresponding to a given target sequence or region
of interest (e.g., DUF1220 clade, non-NBPF gene, etc.) were
averaged for an average linear ratio for that gene or region
(Figure S1A, step 2). Next, all single-locus probes (i.e., probes cor-
responding to single-copy genome sequences excluding chromo-
somes 1, X, and Y) were averaged (Figure S1A, step 3). An adjusted
score, for which the average linear ratio for a target region (from
step 2) was divided by the average linear ratio of all single-locus
probes (from step 3) (Figure S1A, step 4), was then generated.
Finally, the resulting normalized linear ratio was then converted
into a log2 ratio, which was then used for statistical analyses. Cy-
tosure Interpret Software was used for viewing segmentations
across chromosome 1 and for generating Figure 1.
So that bias could be reduced from cross-hybridizing probes
aligning to multiple clade types (e.g., HLS1 and CON3), in the
clade analysis all nonunique probes mapping to multiple clade
types (21%) were removed from the analysis. The nonunique
probes that mapped to only a single clade type were retained,
and the values assigned to each clade type represent an average
of the signals obtained for each probe within a clade type.
However, some cross-hybridization of probes to multiple genomic
regions of the same clade type, such as to multiple HLS1 regions,
remained.
The region from each 1q21 gene’s transcription start coordinate
to each gene’s transcription stop coordinate was divided into
nonoverlapping windows of 500 bases so that the array results
could be viewed for each 1q21 gene (for example, Figures 2B–
2D). For each sample tested, the log2 ratio values for all probes
whose coordinates mapped within each window were averaged
and plotted for each gene.
For viewing the DUF1220 regions on the basis of clade classifica-
tion, the sequence spanning each DUF1220 repeat (clade span;
Figure S1B) located in the 1q21 region (Figure 3B) was used as
a separate window and the average log2 ratio was calculated on
the basis of all probes that aligned within each window. Each
DUF1220 window was first ordered by its clade classification and
then by its genomic coordinate within each clade classification
(Figure 3B).
qPCR Analysis
Quantitative real-time PCR (qPCR), with the use of Taqmanmaster
mix on an Applied Biosystems 7300 Real-Time PCR system, was
carried out on genes for each individual with optimal primer446 The American Journal of Human Genetics 91, 444–454, Septemband fluorogenic probe sets that are unique to the DNA
sequence of the gene of interest. Optimal primers and probes
were designed with PrimerExpress (Applied Biosystem software).
The amplicon sequence was used as a BLAT query against
the human March 2006 (hg18) assembly for verifying that the
primer and designs were sound. The functionality of each primer
pair was then verified with the UCSC database for in silico
PCR. Primer oligos were obtained from Thermofisher/Operon
(Huntsville, AL).
Relative copy-ratio estimates were generated with the standard
curve method, normalized to CFTR, cystic fibrosis transmembrane
conductance regulator (ATP-binding cassette subfamily C, mem-
ber 7), an ATP-binding cassette that was used as a control gene
thought to represent one gene per haploid human genome.14
Reactions were carried out in triplicate per plate run and replicated
in at least three separate plate reaction runs. In total, DNA was as-
sayed at least nine times per individual. Copy ratios of all assays
were averaged for the final ratio measure. Additionally, qPCR-
derived copy ratio of DUF1220 domains was compared to aCGH
copy ratio on 26 individuals with known CNVs in the 1q21.1-
1q21.2 region. The qPCR primer and probe sequences are listed
in Table S2.
Statistical Analyses
To test our primary hypothesis that DUF1220 copy-number ratio
is associated with head circumference, we tested for association
between the copy number of each of the sequences of interest
and frontal occipital circumference (FOC) Z scores via linear
regression models. Because of a priori hypotheses regarding the
biologic relevance of DUF1220 copy number to brain size, our
primary inference was based on six tests that we performed by
using the 42 samples from individuals with either microcephaly
or macrocephaly. One test was conducted for each of the three
conserved DUF1220 clades (CON1, CON2, and CON3), and one
was conducted for each of the HLS clades (HLS1, HLS2, HLS3).
In each case, the average of the log2 ratio of the individual
sequences was used as the measure for a clade. Secondary analyses
were stratified according to whether an individual had a deletion
(n ¼ 26) or a duplication (n ¼ 16) in the 1q21.1-1q21.2 region.
On the basis of the results of the stratified analyses, we conducted
tertiary (exploratory) analyses to test for association between each
of the other genes assayed by aCGH and the FOC Z scores among
the deletion subgroup. The ethnic distribution of individuals with
known deletions or duplications was categorized as 26 white, 12
Hispanic, and 3 African American or other. Differences of
copy ratio between ethnic groups were tested with a one-way
ANOVA. We assessed population stratification in the group with
a known deletion by including ethnicity as a covariate in a linear
regression model of FOC Z score and CON1. There was no
evidence of (1) a significant difference of copy ratio between
ethnic groups (p > 0.10), (2) confounding by ethnicity, or (3)
an association between ethnicity and FOC Z scores. Given the
lack of ethnic associations, results presented below are from unad-
justed regression models.
For aCGH studies of a nondisease population, a sample of 59
unrelated non-Hispanic white individuals was selected from a
cohort of greater than 300 individuals for extremes in brain size.
For this selection, gray-matter residual volumes were obtained
from a regression controlling for sex and age. The 59 individuals
selected for analysis had gray-matter residual volumes greater
than 0.5 (large group, n ¼ 29) and less than 0.5 (small group,
n ¼ 30). We selected extremes in phenotypes to potentiallyer 7, 2012
Figure 1. CytoSure Images of Disease-Population aCGH Data on 1q21.1-1q21.2
aCGH data for the disease population subdivided into class I deletions (smaller), class II deletions (larger), and duplications. Regions
highlighted in blue denote copy-number aberrations.increase our power to detect differences in copy ratio between
groups. We selected non-Hispanic white individuals to control
for potential population stratification. This population wasThe American69.5%male and had a mean age of 10.9 years and a standard devi-
ation (SD) of 3.0 years. We first tested for association between each
of the six DUF1220 clades and having a large or small gray-matterJournal of Human Genetics 91, 444–454, September 7, 2012 447
Figure 2. aCGH Data for Disease Samples from Three Genes in
the 1q21.1-1q21.2 Region
Class I duplications are shown in magenta, class I deletions are
shown in teal, and class II deletions are shown in black.
(A) Graph of rank-ordered FOC Z scores for samples within each
disease class.
(B) BCL9.
(C) GPR89.
(D) NBPF20.residual volume (on the basis of the selection criteria described
above) via t tests. Lastly, in an exploratory analysis, we tested for
association of large or small gray-matter volume versus aCGH-pre-
dicted copy ratio of other genes in the 1q21 region. Analyses were
conducted with R version 2.10.1.448 The American Journal of Human Genetics 91, 444–454, SeptembResults
Microcephaly and Macrocephaly
To directly investigate the possible involvement of
DUF1220 copy number in 1q21.1-1q21.2 microcephaly
and macrocephaly, we designed custom 1q21 microarrays
to more comprehensively cover the 4.4 Mb 1q21.1-1q21.2
interval, as well as the sequences flanking the interval. In
addition, we developed new bioinformatic tools that al-
lowed the copy number of different types of DUF1220
sequences to be independently assessed. The arrays were
used for high-resolution aCGH analysis (Figure S1) of 42
individuals (Table S3) with either 1q21.1-1q21.2 deletions
(class I [smaller] or class II [larger]) or duplications. As orig-
inally defined by Brunetti-Pierri et al.,6 class I deletions
include a deletion in the distal 1q21.1-1q21.2 region
(hg18), whereas class II deletions are larger and include
the TAR syndrome (MIM 274000) region in addition to
the 1q21.1-1q21.2 region. Of these individuals, 28 harbor
1q21 CNVs associated with microcephaly and macroce-
phaly and were identified from a previous, low-resolution
genome-wide aCGH survey of >16,000 individuals.6 Also
tested were an additional 14 individuals who had similar
1q21 CNVs and who were not previously described. In all
cases, the same reference sample, a single unaffected
male, was used, allowing all test samples to be indirectly
compared to one another. For those samples (n ¼ 28) that
had been previously analyzed by lower-resolution aCGH,
resulting custom 1q21 array data confirmed what had
been previously reported but also allowed specificmeasure-
mentofDUF1220 copynumber andmoredetailed coverage
of the 1q21 region (Figures 1 and 3A).
In order to visualize DUF1220-specific aCGH signals, we
plotted data for each of the 241 human DUF1220-domain-
encoding copies in the 1q21.1-1q21.2 region in six clade-
specific groupings (Figure 3B). Resulting data profiles for
each individual tested from the disease population show
that, overall, the class II deletion group lost more
DUF1220 copies than did the class I deletion group for
all six DUF1220 clades, whereas the duplication group
gained DUF1220 sequences. qPCR independently con-
firmed these trends (Figure S2 and Table S4).
aCGH-predicted copy-number values of DUF1220-
domain-encoding sequences (included in NBPF genes)
and non-NBPF sequences within the 1q21.1-1q21.2 region
were next compared to head-circumference values (FOC
Z scores) for each sample. The resulting data from the
entire disease population (class I and class II deletion
groups and the duplication group) indicate that the copy
number of DUF1220 sequences (clades CON1–CON3 and
HLS1–HLS3) shows a strong correlation with FOC Z scores
(Table 1 and Figure 4). In addition, a number of other
genes within the region also exhibit a significant correla-
tion with FOC Z scores (Table S5), confirming results
from the previous low-resolution aCGH analysis of these
samples.6er 7, 2012
Figure 3. aCGH Data for Three Types of
Disease Samples
Class I duplications are shown inmagenta,
class I deletions are shown in teal, and
class II deletions are shown in black.
(A) Array data for the entire 1q21.1-1q21.2
region. Sequence gaps are displayed as
vertical gray bars. Because of space limita-
tions, only the NBPF gene family, BCL9,
and GPR89 are labeled.
(B) DUF1220 clade array profile. Log2
ratios corresponding to DUF1220 signals
are shown for individual samples from
the three classes of the disease population.
aCGH data for each individual are plotted
as a continuous horizontal line so that
results from individual samples can be
distinguished from one another. For each
sample tested, data points are first grouped
according to clade and then within each
clade, they are grouped in the order in
which they occur across the 1q21 region.
The numbers of DUF1220 domains
belonging to each clade are represented
as tick marks along the x axis. The number
displayed below represents the number of
DUF1220 domains found within each
clade. The marks represent 238 clade-
specific DUF1220 domains located in the
1q21 region and present on the custom
array. Phylogeny of the six clades
(CON1–CON3 and HLS1–HLS3) is dis-
played at the top.To determine which sequences were driving this
association, we stratified the samples by deletion (class I
and class II combined) or duplication groups in the 1q21
region. Analysis of the duplication group alone demon-
strated no evidence of association between head circumfer-
ence and any 1q21.1-1q21.2 sequences, including those of
DUF1220 (data not shown). However, using array data
from the combined class I and class II deletion groups,
we found an association between head circumference
and the copy number of each of the six DUF1220 clades.
The strongest association was obtained with the three
evolutionarily conserved DUF1220 clades (CON1, p ¼
0.0079; CON2, p¼ 0.0134; and CON3, p¼ 0.0116), where-
as a significant, though more modest, association was
found for the three HLS clades (HLS1, p ¼ 0.0476; HLS2,
p ¼ 0.0431; and HLS3, p ¼ 0.0444) (Table 2 and Figure 4).
Interestingly, all NBPF (i.e., DUF1220-encoding) genes that
map to 1q21 showed a significant association (p < 0.044)
with head circumference (on the basis of FOC Z scores)
in the deletion group (Table 3). Except for C1orf54, no
significant association was found (p < 0.05) for any of
the 40 non-DUF1220-encoding genes in the critical region
or adjacent to the implicated deletion interval (Table S6).
Although C1orf54 shows a correlation with head circum-
ference in the deletion group, this gene is found outside
the critical region for microcephaly and macrocephaly, as
previously defined by Brunetti-Pierri, et al.,6 and showsThe Americanno significant association with FOC Z scores across the
full disease population (i.e., 1q21-associated microcephaly
and macrocephaly) (Table S5). It also does not exhibit
correlative evolutionary evidence as seen in the dramatic
copy-number increase of DUF1220 sequences. For the
above reasons, C1orf54 is most likely a false-positive associ-
ation. Taken together, these findings implicate loss of
DUF1220 copy number in 1q21-associated microcephaly.
In addition, it should be noted that these results do not
eliminate an increase in DUF1220 copy number as the
likely cause of 1q21-associated macrocephaly in these
samples, although definitive proof of its involvement will
most likely require analysis of additional samples and/or
finer copy-number measurements.
The change in FOC-Z-score distribution across these
disease samples reflects a gradual, rather than abrupt,
profile (Figure 2A), suggesting that any gene (or domain)
whose dosage underlies these changes should also show
a similar distribution. Indeed, unlike single- or low-copy
sequences, the high copy number of DUF1220 sequences
allows them to be incrementally reduced over an ex-
tremely broad copy-number range. For example, single-
copy 1q21 genes, such as BCL9 (Figure 2B), show only
two discrete array profiles: one for the deletion groups
and one for the duplication group. Genes, such as GPR89
(Figure 2C), with a copy in the intervals for both the class
I and class II deletion groups, show only three primaryJournal of Human Genetics 91, 444–454, September 7, 2012 449
Figure 4. Correlation between FOC Z Scores and aCGH Copy
Ratios for DUF1220 CON1 Clade Sequences
Correlation between FOC Z scores and aCGH-based copy ratio of
CON1 DUF1220 sequences within the disease population. CON1
copy ratio and FOC Z scores are displayed on the x axis and y
axis, respectively. Individuals with class I deletions (aqua), class
II deletions (black), and duplications (purple) are plotted against
their FOC Z score.
Table 1. Correlation between aCGH-Predicted DUF1220 Clade
Copy Number and FOC Z Scores for the Entire Disease Population
Clade Beta SE R2 p Value
CON1 7.301 1.151 0.501 1.56 3 107
CON2 7.125 1.136 0.496 1.97 3 106
CON3 6.826 1.172 0.459 8.29 3 107
HLS1 4.067 1.021 0.284 0.0003
HLS2 3.703 0.978 0.264 0.0005
HLS3 3.599 0.969 0.256 0.0006
Significant (p% 0.05) associations are shown in bold. Beta is the effect estimate
of 1 unit increase in copy ratio from a linear regression model. The following
abbreviation is used: SE, standard error of beta.levels of copy number. In contrast, DUF1220 clades, such
as those from NBPF20 (Figure 2D), show a continuous
copy-number profile that closely resembles the gradual
distribution of FOC Z scores across these samples
(Figure 2A).
Nondisease Population
To investigate whether DUF1220 copy number might
contribute to population variation in a brain-size-related
phenotype in a nondisease population, we implemented
the same custom 1q21.1-1q21.2 aCGH analysis on 59
individuals with extremes of normal variation of brain
gray-matter volume. Although this phenotype is distinct
from that found in the disease population, it provides
an analysis of a related brain phenotype in an indepen-
dently generated, nondisease cohort. After classifying indi-
viduals into large and small gray-matter groups, we tested
DUF1220 sequences for mean copy-number differences
between groups by using t tests. The mean CON1 and
mean CON2 copy-number values were both significantly
greater in the large gray-matter group than in the small
gray-matter group (p ¼ 0.0246 and p ¼ 0.0334, respec-
tively) (Figure S3 and Table S7). Notably, the CON1 clade
also showed the strongest association with head circumfer-
ence in the deletion group of the disease population.
Subsequent analysis, which included 40 additional genes
not related to NBPF genes but located in the 1q21.1-1q21.2
region, resulted in the ancestral DUF1220-containing gene,
PDE4DIP, and four non-DUF1220-containing genes—
SEC22B,NUDT17, SV2A, and SF3B4—showing a significant
association between gray-matter volume and aCGH-pre-
dicted copy number (p < 0.048; Table S8). However, three
of these genes (NUDT17, SV2A, and SF3B4) show a negative
correlation with gray matter and thus exhibit an inverse
relationship with brain size. Additionally, SEC22B, SV2A,
and SF3BF lie outside the critical 1q21.1-1q21.2 region
previously linked to microcephaly and macrocephaly, and
none of the four genes show an association with brain
size in the disease population. Finally, unlike the close
parallel that DUF1220-domain copy number shows with
evolutionary changes in brain size, none of these genes450 The American Journal of Human Genetics 91, 444–454, Septembexhibit such complementary evolutionary evidence (all
four genes are single copy across primate lineages; Table
S9). These observations strongly suggest that these genes
most likely represent false-positive correlations. Impor-
tantly, none of the other non-DUF1220-containing genes
that map within the critical region show any correlation
with head circumference in the group of healthy individ-
uals and are probably not influencing human brain size
under normal conditions.
The very strong association identified for CON1 (p ¼
1.56 3 107), CON2 (p ¼ 1.97 3 106), and CON3 (p ¼
8.29 3 10-7) in the entire disease population is most likely
indicative, in part, of the substantial range in FOC Z scores
(>54 SDs) observed in this group. In contrast, the sample
of healthy individuals, does not exhibit such wide varia-
tion, which ranges only from <53 SDs, even though it
shows head-circumference extremes. For these reasons,
the more modest, but still significant, association between
gray-matter residual values and CON1 and CON2 (p ¼
0.0246 and p ¼ 0.0334, respectively; Table S7) could be
expected given the relatively small sample size and the
comparably lower range of brain volumes in a group of
healthy individuals.Discussion
Here, we have shown that of all the 1q21 genes examined
(n ¼ 53), only DUF1220 sequences exhibit a significant
direct correlation with brain-size phenotypes in both
pathological and normal human populations. Although
we provide data implicating the loss of DUF1220 copy
number in 1q21-associated microcephaly, the data are
also fully consistent with the view that increases iner 7, 2012
Table 2. Correlation of aCGH-Predicted DUF1220 Clade Copy
Number with FOC Z Scores for the Combined Class I and II Deletion
Groups
Clade Beta SE R2 p Value
CON1 4.128 1.425 0.259 0.0079
CON2 3.421 1.282 0.229 0.0134
CON3 3.108 1.137 0.237 0.0116
HLS1 1.472 0.705 0.154 0.0476
HLS2 1.430 0.669 0.160 0.0431
HLS3 1.376 0.648 0.158 0.0444
Significant (p% 0.05) associations are shown in bold. Beta is the effect estimate
of 1 unit increase in copy ratio from a linear regression model. The following
abbreviation is used: SE, standard error of beta.
Table 3. Association between Average aCGH-Predicted Copy
Ratios for NBPF Genes in the 1q21 Region and FOC Z Scores in the
Deletion Group
Gene Beta SE R2 p Value
NBPF8 1.431 0.673 0.159 0.044
NBPF9 2.741 1.087 0.210 0.019
NBPF10 1.615 0.740 0.165 0.039
NBPF11 2.708 1.080 0.208 0.019
NBPF12 2.280 0.955 0.192 0.025
NBPF13 2.557 1.047 0.199 0.022
NBPF14 1.662 0.754 0.168 0.037
NBPF15 3.219 1.206 0.229 0.013
NBPF16 3.052 1.154 0.226 0.014
NBPF20 1.465 0.684 0.161 0.042
NBPF23 4.621 1.617 0.254 0.009
NBPF24 2.649 1.063 0.203 0.020
NBPF25 1.815 0.810 0.173 0.035
Significant (p% 0.05) associations are shown in bold. Beta is the effect estimate
of 1 unit increase in copy ratio from a linear regression model. The following
abbreviation is used: SE, standard error of beta.DUF1220 copy number underlie 1q21-associated macroce-
phaly.
We also note that the microcephaly and macrocephaly
samples tested here were identified with lower-resolution
aCGH platforms that restricted analyses to single-copy
sequences and therefore did not directly examine
DUF1220 copy number. As a result, the disease samples
that were tested were all biased to contain only large
1q21 CNVs with imprecise breakpoint estimates. Because
each DUF1220 domain repeat is on average only 1.8 kb,5
it is likely that gain and loss of DUF1220 sequences,
accompanied by negligible changes in flanking single-
copy sequences, frequently occur and are invariably
missed with current aCGH approaches. These observations
suggest that there are likely to be a substantial number of
microcephaly and macrocephaly cases that are due to
DUF1220 CNVs that have yet to be identified.
Although the studies described here link DUF1220 copy
number to pathological and normal variation in brain size,
independent evidence is also consistent with its involve-
ment in human brain evolution. Among primate lineages,
there is a high correlation between DUF1220 copy number
(the highest copy number, >270, was found in Homo
sapiens [human and Neanderthal]) and increased brain
size (R2 ¼ 0.98; p ¼ 1.8 3 106) (Figure S4A), as well as
an increased number of cortical neurons (R2 ¼ 0.98; p ¼
0.0011) (Figure S4B). Unlike DUF1220-domain-encoding
sequences, other genes in the 1q21 region are virtually
all single to low copy among primates, and none show a
strong correspondence between copy number and primate
brain size (Table S9). Taken together, these observations
support the view that DUF1220-domain copy number,
i.e., DUF1220-domain dosage, functions as a general
effector of evolutionary, pathological, and normal varia-
tion in brain size.
Although the copy number of all NBPF (i.e., DUF1220-
encoding) genes showed significant association with
head circumference in the complete disease sample set,
as well as in the combined deletion group, we also looked
for associations by using DUF1220 domains that had
been separated into specific phylogenetic clades. ResultingThe Americancopy-number profiles of the six DUF1220 clades indicated
that the copy number of conserved DUF1220 clades CON1
and CON2 exhibited a stronger correlation with brain size
in the disease and nondisease populations than did that of
the HLS clades. This bias might be related to the finding
that a specific clade order is maintained within each
NBPF gene: the CON1 and CON2 clades are found nearest
to the NBPF gene region encoding the N terminus of the
predicted protein, whereas the other clade sequences are
more distally located.5 Thus, loss of CON1 and CON2
sequences could be expected to frequently result in com-
plete loss of gene function (even if downstream DUF1220
sequences were not deleted) because the promoter region
and/or transcription start site are more likely to be
included in a loss of sequence that contains the gene
regions encoding the N terminus of the predicted protein.
This might result in a more pronounced effect on pheno-
type compared to loss of other DUF1220 clade sequences,
which lie in the middle and C-terminal regions of the
predicted proteins. Alternatively the bias might be a reflec-
tion of technical issues, e.g., accurately measuring the
higher copy number of the HLS clades, compared to the
CON clades, is typically more difficult. Finally it is also
possible that the CON and HLS clades carry out distinct
functional roles and, as a result, influence different brain
phenotypes.
The capacity of DUF1220 sequences to undergo frequent
duplications and deletions is most likely related, at least
in part, to their organization in the genome. DUF1220
sequences that lie within the 1q21 region are generally
found in two distinct arrangements: (1) within the 13Journal of Human Genetics 91, 444–454, September 7, 2012 451
Figure 5. DUF1220 Model Linking 1q21.1-1q21.2 Instability,
DUF1220-Domain Copy Number, Brain Evolution, and Recurrent
Disease
*Twelve genomic diseases have been linked to CNVs in the 1q21.1-
1q21.1 region. They are listed in Table S1 and include autism,
congenital heart disease, congenital anomaly of the kidney and
urinary tract, epilepsy, intellectual disability, intermittent explo-
sive disorder, macrocephaly, Mayer-Rokitansky-Ku¨ster-Hauser
syndrome, microcephaly, neuroblastoma, schizophrenia, and
thrombocytopenia-absent-radius syndrome.predicted NBPF genes, which are primarily interspersed
throughout the 1q21 region and are separated by single-
or low-copy-number non-NBPF genes, and (2) tandemly
ordered within individual NBPF genes. Such an organiza-
tion provides a number of different options throughwhich
copy number can be easily altered. One or a combina-
tion of mechanisms could underlie these changes; such
mechanisms include nonallelic homologous recombina-
tion (NAHR), DNA-replication-based mechanisms, and
possibly mitotic recombination. Specifically, NAHR events
could occur during meiosis and cause either duplications
or deletions of a few or many DUF1220 sequences or
even of entire gene regions. Alternatively, DNA-replica-
tion-based mechanisms might also be involved in changes
in DUF1220 copy number. As a result of the numerous
DUF1220 tandem duplications found in the human
genome,5 replication slippage might occur during DNA
synthesis inwhich either the template or a newDNA strand
loops out and causes deletions or duplications, respective-
ly; another possibility might be long-distance template-
switching mechanisms.15 These processes could produce
rapid localized increases in DUF1220 copy number, such
as the human-specific evolutionary hyperamplifications
noted by O’Bleness, et al.,5 as well as in the variations
in DUF1220 copy number observed here within human
populations.
Utilizing lower-resolution bacterial artificial chromo-
some (BAC)-based arrays, Brunetti-Pierri et al.6 postulated
thatHYDINmight be a plausible candidate gene important
to brain-size differences seen between individuals with
1q21-related microcephaly and macrocephaly. Our data,
obtained with higher-density custom 1q21 arrays, show
no suggestive evidence that this is the case, either in
disease or nondisease populations. Because Brunetti-Pierri
et al. used conventional BAC arrays with large probes
that targeted only unique sequences, small regions and
highly-duplicated sequences that might be important
to causing microcephaly and macrocephaly could have
been missed. Also, from an evolutionary standpoint,
no genes, including HYDIN, show a high correlation
between copy number and primate brain size. Likewise,
no genes, except those encoding DUF1220 domains,
show a correlation with both pathological-associated
head size and human-population variation extremes for
brain gray-matter volume. Although HYDIN might be
involved in hydrocephaly (MIM 610813), our data provide
no support for its involvement in the brain-size differences
that have occurred over the course of primate evolution.
Regarding the mechanism by which DUF1220 acts,
we have previously proposed links among DUF1220
domains, microcephaly, and the centrosome.4,8 The cen-
trosome is a key mitotic regulator that determines when
cells switch from symmetric to asymmetric cell division.
The timing of this switch is essential for neuronal migra-
tion during brain development and can profoundly influ-
ence neuron number and brain size. Almost all known
microcephaly-associated genes encode centrosomal pro-452 The American Journal of Human Genetics 91, 444–454, Septembteins and one, CDK5RAP2, is a homolog of PDE4DIP,
which encodes a centrosomal protein that contains a
copy of the ancestral form of DUF1220. In addition, the
EVI5 promoter has recently been recruited to the regula-
tory region of several NBPF genes.16 Interestingly, EVI5 is
known to encode a centrosomal protein,17 suggesting a
possible means by which DUF1220 domains might be tar-
geted to the centrosome.
Finally, the data presented here provide additional sup-
port to a previously described model that links DUF1220’s
recent evolutionary copy-number burst to the large
number of 1q21 CNVs that have been reported to be asso-
ciated with disease (Figure 5 and Table S1). The model
proposes that the adaptive value conferred by increasing
DUF1220 copy number has resulted in favoring the reten-
tion of the high instability of the 1q21.1-1q21.2 region;
this, in turn, has given rise to the unusually high number
of recurrent disease-associated CNVs that have been re-
ported for this region.8 There are an estimated 13 NBPF
genes (encoding a total of 240 DUF1220 repeats) that
map to the 1q21.1-1q21.2 region; these are often
separated by several single-copy, non-DUF1220 genes,
producing a highly disease-prone genome architecture
(Figure S5). In such an environment, the large number
of nontandem, DUF1220-repeat-rich NBPF genes in this
region can be expected to produce frequent NAHR events
between NBPF genes that will often carry along (i.e., dupli-
cate or delete) the intervening single-copy genes. In this
sense, although DUF1220 copy number by itself appears
to be directly related to evolutionarily advantageous
increases in brain size, the dosage imbalance (generated
by illegitimate DUF1220-driven recombination events) of
the single-copy 1q21.1-1q21.2 genes might produce the
unusually diverse pathologies that have been reported for
disease-associated 1q21.1-1q21.2 CNVs. In summary,
although hyperamplification of DUF1220 copy number iser 7, 2012
among the most remarkable HLS changes found in the
genome and has ramifications related to human brain
evolution, it has come—and continues to come—at an
expensive price given that it has been largely responsible
for creating and maintaining one of the most unstable
and disease-prone regions of the human genome.Supplemental Data
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